5 OARO - ICH (Question Answers)
-
Upload
obaid-ali-roohi-b-obaid -
Category
Leadership & Management
-
view
443 -
download
2
Transcript of 5 OARO - ICH (Question Answers)
![Page 1: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/1.jpg)
Questions, Answers,
Comments & Clarifications
Obaid AliCivil Service Officer, Member, ISPE, PDA
26 March 2017
![Page 2: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/2.jpg)
Not the view of DRAP
Current judgment
No obligation on DRAP
Regulatory experience
D
I
S
C
L
A
I
M
E
R
References US-FDA WHO ICH NRAs
![Page 3: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/3.jpg)
![Page 4: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/4.jpg)
![Page 5: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/5.jpg)
Intermediate Studies
Intermediate Studies Required …. Yes/ No
If Yes ….
When (What is appropriate time to introduce) & Why?
![Page 6: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/6.jpg)
All together with
Accelerated and long term
To encounter in case of
failure of accelerated
![Page 7: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/7.jpg)
Significant change at Accelerated
Condition
What should be done?
If one among the three batches in accelerated conditions
show a significant change
![Page 8: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/8.jpg)
Intermediate data of all three
batches need to be submitted
Furthermore, a failure
analysis focusing discussion
outcome on the observed
discrepancies
![Page 9: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/9.jpg)
Data provision
in weeks instead of months
Can the recommendation for 6 month accelerated
stability data be met by providing 24 weeks of data (as 12 weeks is usually accepted equivalent to 3 months)
![Page 10: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/10.jpg)
No, it cannot be
ICH stability guidance
refer to timeframes in
terms of months not
weeks
![Page 11: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/11.jpg)
One Bulk Solution for
Three Batches
Can the split bulk solution filled into different fill
volumes be considered separate batches?
![Page 12: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/12.jpg)
NO
3 Batches of different
bulk solution, not from a
single bulk solution
![Page 13: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/13.jpg)
Size of lab scale batch
What is meant by Lab (3rd small) scale?
![Page 14: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/14.jpg)
Oral dosage forms
NLT 25% of the
pilot scale batch
Powders/solutions/
suspensions
NLT 25% of the
pilot scale batch Transdermal patches
NLT 60% of the
pilot scale batch
![Page 15: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/15.jpg)
Parenteral
NLT 25% of the pilot scale batch
(50 Lit if unit is > 2ml)
(30 Lit if unit is up to 2ml)
Cream/ Ointment/Gel
Not less than 40% of Pilot
(At least 100 kg or 10% of
proposed commercial batch,
whichever is larger)
![Page 16: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/16.jpg)
Manufacturing outside
GMP zone
Is it acceptable to manufacture small scale batches in a
outside GMP (University etc.)?
![Page 17: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/17.jpg)
NO
All generic submission
batches should
manufactured following
cGMP
![Page 18: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/18.jpg)
Sterile product
in a non-sterile facility
Is it wrong to manufacture small scale batches for sterile
products in a non-sterile facility?
![Page 19: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/19.jpg)
Yes
It is wrong
Sterility, particulate
matter etc. are critical
attributes of sterile
products
![Page 20: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/20.jpg)
Small scale in
commercial equipment
Can a small scale batch be produced at the commercial
drug manufacturing facility?
![Page 21: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/21.jpg)
Yes
It is always good
In this way,
understanding &
knowledge will give
more efficient strategy
of control
![Page 22: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/22.jpg)
Position of Products
in a Stability Program
Is the placement position of drug
in a Stability Chamber, a matter of concern?
![Page 23: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/23.jpg)
For liquids, solutions,
semi-solids and
suspensions, the products
should be placed in an
inverted or horizontal
position and an upright or
vertical position.
In case of routine stability
studies, one should pick
the worst case orientation
![Page 24: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/24.jpg)
Preservative Effectiveness &
Number of Batches
What do you think, how many batches?
1 or 2 or 3 or more
![Page 25: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/25.jpg)
Content in 3 lots Effectiveness in one lot
![Page 26: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/26.jpg)
Extractable Leaching Testing &
Number of Batches
What do you think, how many batches?
1 or 2 or 3 or more
![Page 27: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/27.jpg)
One time
Rationale to go for more
if any change in
container/closure, then
rationale exist
…. Anything you may
contribute ….
![Page 28: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/28.jpg)
Active Pharmaceutical Ingredient &
Generics
How many lots of API
1 or 2 or 3 …. or 5 … or 10 …
![Page 29: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/29.jpg)
Minimum 2 lots for
3 primary batches
But
3 lots for nasal
aerosols or sprays
(formulations)
![Page 30: 5 OARO - ICH (Question Answers)](https://reader034.fdocuments.in/reader034/viewer/2022042619/58eca7b01a28ab505b8b45c5/html5/thumbnails/30.jpg)